4th coronavirus vaccine for the United States; scientists say bullet could end pandemic – WISH-TV | Indianapolis News | Indiana weather

by



[ad_1]

INDIANAPOLIS (WISH) – A fourth coronavirus vaccine is making its way to the United States.

Health experts say the vaccine, Covavax, is the most effective to date showing protection against the original COVID-19 strain, but also against worrisome variants.

Researchers at 113 sites across the country evaluated 29,000 infected patients. Results of the to study has been shown to be 100% effective against the original SAR-CoV-2 and 93% effective against alpha and delta strains, both of which are on the World Health Organization’s list of variants of concern.

But what is so special about Covavax about Pfizer, Moderna and Johnson & Johnson?

Dr Stephaun Wallace, who leads the global COVID-19 outreach strategy network Prevention Network at the Fred Hutchinson Cancer Research Center, receives his second injection from Dr Tia Babu during the Phase 3 clinical trial of the Novavax COVID-19 vaccine at the UW Virology Research Clinic on February 12, 2021 in Seattle, Washington. (Photo by Karen Ducey / Getty Images)

“What they do is produce an immunogenic protein, which appears to be a stable part of the coronavirus as the virus mutates,” Dr Christopher Doehring, vice president of medical affairs at Franciscan Health, told News 8. . piece helps [the vaccine] be delivered into the human body and allows the immune system to recognize it effectively and develop a robust response.

Not only does Covavax offer high protection, says Doehring, but the side effects are milder compared to other vaccines. Reported side effects include tenderness at the injection site, headache, and mild fatigue. On average, the symptoms lasted for three days.

The European Union has reached an agreement with the pharmaceutical company responsible for the development of the vaccine, Novavax. They will buy 200 million doses, which is a two-shot protocol, of the vaccine.

Novavax is expected to apply for emergency use authorization in the United States by the end of the year.

[ad_2]

Source link